Skip to content

Clinical trials

Lower Urinary Tract Symptoms trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Lower Urinary Tract Symptoms Phase: Not applicable Clear all

169 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20001
20041
20062
20083
20101
20122
20134
201413
20155
20167
201711
201812
20198
202010
202113
202215
202321
202413
20257
202618

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed78
Unknown status33
Recruiting23
Not yet recruiting12
Active, not recruiting11
Withdrawn8
Terminated2
Enrolling by invitation2

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
PROCEPT BioRobotics4
Beni-Suef University3
Rigshospitalet, Denmark3
Ambu A/S2
Benha University2
Boston Scientific Corporation2
Cairo University2
Centre hospitalier de l'Université de Montréal (CHUM)2
Chiara Zecca2
I.M. Sechenov First Moscow State Medical University2

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Lower Urinary Tract Symptoms169
Prostatic Hyperplasia73
Urinary Bladder, Overactive16
Urinary Incontinence16
Multiple Sclerosis10
Prostatic Neoplasms7
Urinary Incontinence, Urge6
Urinary Retention6
Anxiety Disorders5
Hyperplasia5

Trials

Showing 51 to 75 of 169. Each trial links to its page on Pharma Observatory.

69 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.